Willem Van Schooten
Principal investigator.
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$1.7MFederal grants as PI6 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
6 awards · $1.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 31, 2020 | NIH | SBIR Phase I Inhibition of CD38 NADase by anti-CD38 antibody: a novel therapy for systemic scleroderma | $221K | — |
| Sep 19, 2019 | NIH | SBIR Phase I Development of an Frα x Frα x CD3 trivalent, biparatopic T-cell engaging antibody to treat high grade serous carcinoma | $298K | — |
| Aug 6, 2019 | NIH | SBIR Phase I CD38 enzyme blocking heavy chain antibodies for Inflammatory Bowel Diseases | $294K | — |
| Jul 23, 2019 | NIH | SBIR Phase I Bispecific Antibodies Directed to CD3and HBsAg to Treat Chronic Hepatitis B Virus | $297K | — |
| Aug 9, 2018 | NIH | SBIR Phase I Development of a PSMA x PSMA x CD3 trivalent, bispecific T-cell engaging antibody to treat Castration Resistant Prostate Carcinoma | $299K | — |
| Feb 28, 2018 | NIH | SBIR Phase I Development of novel heavy chain antibody-based therapeutics for polyomavirus infections | $291K | — |
Peer ranks
Federal funding#251
Awards as PI#117
Patents#27
Companies
No tracked company linked yet.
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.